FHTX
Foghorn Therapeutics Inc.
FHTX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over FHTX overall, supported by stronger fundamentals and lower modeled downside.
FHTX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
FHTX's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FHTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 34x | $2.05 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FHTX has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FHTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FHTX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
FHTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.06 | +$1.12 |
| Q2 2026 | -$0.99 | +$0.13 |
| Q1 2026 | -$1.17 | +$0.12 |
| Q4 2025 | -$1.18 | +$0.40 |
| Q3 2025 | -$1.06 | +$0.86 |
| Q2 2025 | -$1.12 | +$0.83 |
| Q1 2025 | -$1.29 | +$0.91 |
| Q4 2024 | -$1.58 | +$0.76 |
FHTX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
FHTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.5M | +925% |
| Q2 2026 | $16.1M | +113% |
| Q1 2026 | $3.3M | -45% |
| Q4 2025 | $9.2M | +224% |
| Q3 2025 | $8.2M | +4.4% |
| Q2 2025 | $7.6M | +9.7% |
| Q1 2025 | $6M | +18% |
| Q4 2024 | $2.9M | -50% |
FHTX's revenue is growing: $84M last quarter, up 925% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 68% | +295 points |
| Q2 2026 | -55% | +224 points |
| Q1 2026 | -660% | -275 points |
| Q4 2025 | -258% | +582 points |
| Q3 2025 | -227% | +79 points |
| Q2 2025 | -279% | +108 points |
| Q1 2025 | -385% | +173 points |
| Q4 2024 | -841% | -399 points |
FHTX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FHTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
FHTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$18.3M | +$610K |
| Q2 2026 | -$17.9M | +$3.1M |
| Q1 2026 | -$25.3M | -$1.3M |
| Q4 2025 | -$22.3M | +$2.7M |
| Q3 2025 | -$18.9M | +$2.5M |
| Q2 2025 | -$21M | +$4.5M |
| Q1 2025 | -$24M | +$5.5M |
| Q4 2024 | -$25M | +$2.6M |
FHTX has burned cash in almost every quarter: −$84M over the past year, against −$89M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FHTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
FHTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +2M shares |
| 1 year | +15% | +9.6M shares |
| 3 years | +73% | +30.6M shares |
| 5 years | +96% | +35.6M shares |
| Available history | +228% | +50.5M shares |
FHTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FHTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -21.0x | Net Cash |
FHTX has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FHTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 3.6 | Oversold |
FHTX's weekly RSI is 35 (neutral) and its Stochastic is 4 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FHTX PE vs Healthcare Sector
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FHTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.17 | 5.5% below |
| 20 week MA | $4.10 | 50% below |
| 50 week MA | $4.60 | 55% below |
| 100 week MA | $4.62 | 56% below |
| 200 week MA | $5.55 | 63% below |
FHTX is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over FHTX on trend strength, trading above more of its moving averages.
FHTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.1 | $24.6 | +36% |
| 2021 | $24.6 | $21.2 | -14% |
| 2022 | $21.2 | $5.70 | -73% |
| 2023 | $5.70 | $6.45 | +13% |
| 2024 | $6.45 | $4.82 | -25% |
| 2025 | $4.82 | $5.40 | +12% |
| 2026 YTD | $5.40 | $2.05 | -62% |
FHTX has finished lower in three of the last six years. It's down 62% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FHTX on returns for 2026, with the stronger performance.